Blood Product Manufacturers Begin New Round Of Fund-Raising
This article was originally published in PharmAsia News
Following the footsteps of Hualan Biological Engineering, Beijing Tiantan Biological Products and Beisheng Pharma, Shanghai RAAS Blood Products will be the fourth blood product company listing on the China stock market. It plans to use the fund to extend its production line and R&D processes. Meanwhile, Hualan Biological Engineering has issued new shares to scale up its manufacturing capacity. Some analysts point out that the recent lethal immunoglobulin incident may result in more stringent supervision and approval of blood product manufacturing and expansion. However, most observers believe that qualified large companies' plans will not be restricted due to the limited supply of blood products; rather, insufficient blood plasma source will directly impact their performance. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.